Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Neng Tang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4401-9454; OpenAlex author ID A5051716713. Sources: OpenAlex.

Their work

Papers
9 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 9

  1. SP1-Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. Co-author DOI 10.1002/advs.202510071↗
  2. CD44 identified as a diagnostic biomarker for highly malignant CA19-9 negative pancreatic cancer. Co-author DOI 10.1016/j.canlet.2025.217713↗
  3. Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression. First author DOI 10.1016/j.canlet.2024.216611↗
  4. Postoperative complications and short-term prognosis of laparoscopic pancreaticoduodenectomy vs. open pancreaticoduodenectomy for treating pancreatic ductal ad… Co-author DOI 10.1186/s12957-023-02909-x↗
  5. Zinc finger protein 91 accelerates tumour progression by activating β-catenin signalling in pancreatic cancer. Co-author DOI 10.1111/cpr.13031↗
  6. Comparisons of Outcomes Between Adolescent and Young Adult with Older Patients After Radical Resection of Pancreatic Ductal Adenocarcinoma by Propensity Score … Co-author DOI 10.2147/cmar.s337687↗
  7. MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer. First author DOI 10.1016/s1875-5364(20)30019-4↗
  8. Mind Bomb 1 Promotes Pancreatic Cancer Proliferation by Activating β-Catenin Signaling. First author DOI 10.1166/jnn.2020.18755↗
  9. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Co-author DOI 10.1016/j.biopha.2018.06.114↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yudong Qiu · 4 shared papers, 2020–2025 · strength 0.70
  2. Xiao Fu · 4 shared papers, 2020–2025 · strength 0.64
  3. Hexing Hang · 3 shared papers, 2024–2025 · strength 0.60
  4. Linxi Zhu · 2 shared papers, 2024–2025 · strength 0.40
  5. Jiatong Tang · 2 shared papers, 2025 · strength 0.39
  6. Chao Yan · 2 shared papers, 2025 · strength 0.39
  7. Hao Cheng · 2 shared papers, 2025 · strength 0.39
  8. Yudong Qiu · 2 shared papers, 2020–2025 · strength 0.35
  9. Zhenglin Ou · 2 shared papers, 2018–2021 · strength 0.26
  10. Guodong Liu · 2 shared papers, 2018–2021 · strength 0.26
  11. Wangsen Cao · 1 shared paper, 2024 · strength 0.21
  12. Yixuan Zhang · 1 shared paper, 2025 · strength 0.20
  13. Wei Wei · 1 shared paper, 2025 · strength 0.20
  14. Chaobo Chen · 1 shared paper, 2023 · strength 0.19
  15. Zhongjun Zhang · 1 shared paper, 2023 · strength 0.19
  16. Shuo Zhang · 1 shared paper, 2023 · strength 0.19
  17. Junjing Zhou · 1 shared paper, 2023 · strength 0.19
  18. Bin Zhang · 1 shared paper, 2023 · strength 0.19
  19. Qi Li · 1 shared paper, 2025 · strength 0.19
  20. Zhenghua Cai · 1 shared paper, 2025 · strength 0.19
  21. Jian He · 1 shared paper, 2021 · strength 0.16
  22. Taiyu Song · 1 shared paper, 2021 · strength 0.16
  23. Hongyan Zai · 1 shared paper, 2021 · strength 0.16
  24. Mujing Ke · 1 shared paper, 2018 · strength 0.10
  25. Yixiong Li · 1 shared paper, 2018 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.